Rejected from JAMA? The 7 Best Journals to Submit Next

• Clinical significance: JAMA wants papers whose findings matter to practicing clinicians across specialties. A cardiologist reading an oncology paper should understand why it's important. That cross-specialty relevance bar is what makes JAMA selective. Highly specialized studies, even excellent ones, get desk-rejected because the readership won't engage with them.

• Methodological rigor: JAMA has some of the strictest standards for study design in all of medicine. The journal expects proper adherence to reporting guidelines: CONSORT for trials, STROBE for observational studies, PRISMA for systematic reviews. Missing a CONSORT flow diagram or failing to pre-register your trial endpoints will raise red flags at the desk.

These two filters work simultaneously. A methodologically flawless paper on a question nobody is debating gets rejected. An important clinical question answered with underpowered data gets rejected. You need both.#

• "The findings are of interest but more suited to a specialty audience.": This is the most frequent desk rejection. Your study is strong, but the topic is too specialized for JAMA's general medical readership. A well-designed hepatology trial, however large, competes against papers in cardiology, oncology, psychiatry, and everything else for limited space.

• "We question whether the study design is adequate.": JAMA's statistical editors are thorough. If your observational study could have been a trial, or your trial has methodological gaps, or your analysis plan changed post-hoc without adequate justification, expect a desk rejection.

• "This topic has been well covered in recent JAMA publications.": Timing matters. JAMA avoids publishing too many papers on the same topic in a short period. Your paper might be strong but arrive when the journal has already committed to three similar manuscripts.

• "Insufficient clinical implications.": Your findings are statistically significant but clinically marginal. A treatment that produces a 2% absolute risk reduction in a non-fatal outcome is harder to place at JAMA than a treatment producing a smaller effect on mortality.

JAMA operates a network of high-quality specialty journals, and editors frequently offer transfers:

• JAMA Internal Medicine (IF ~23) - General internal medicine, health services- JAMA Oncology (IF ~28) - Cancer clinical research- JAMA Cardiology (IF ~14) - Cardiovascular medicine- JAMA Neurology (IF ~20) - Neurological disorders- JAMA Surgery (IF ~15) - Surgical outcomes- JAMA Psychiatry (IF ~22) - Mental health- JAMA Pediatrics (IF ~20) - Child and adolescent health- JAMA Dermatology (IF ~12) - Skin disease- JAMA Network Open (IF ~13) - All medical specialties, open accessJAMA Network Open deserves special mention. It publishes across all clinical areas, it's fully open access, and its acceptance rate (~15%) is more realistic than JAMA's. For papers that JAMA found interesting but not quite competitive for the flagship, JAMA Network Open is often the perfect fit.

Before choosing your next journal, a JAMA manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

• Large clinical trial desk-rejected?: Go to NEJM or The Lancet first. If both say no, then consider JAMA Internal Medicine or Annals. Don't skip the top tier just because JAMA said no.

• Specialty trial desk-rejected?: Accept the JAMA network transfer if offered. JAMA Oncology, JAMA Cardiology, or JAMA Neurology carry more weight in their specialty than most papers in JAMA's general pages. If no transfer is offered, submit to the relevant JAMA specialty journal independently.

• Systematic review or meta-analysis rejected?: The BMJ is the strongest alternative. Annals of Internal Medicine is also strong for reviews that inform clinical practice guidelines.

• Rejected after peer review?: Fix what reviewers flagged. JAMA reviewers provide detailed, specific feedback. Address every point, then submit to NEJM, The Lancet, or The BMJ with a note that your paper has been peer-reviewed and revised.

• Check your reporting compliance: JAMA's most common fixable rejection trigger is incomplete reporting guideline adherence. If you submitted a trial without a proper CONSORT flow diagram, or an observational study without STROBE compliance, fix this before submitting anywhere. The BMJ and NEJM check the same things.

• Reframe for the new audience: JAMA readers are US-leaning generalists. NEJM readers are practice-focused clinicians. The Lancet readers think globally. The BMJ readers care about evidence quality and policy. Adjust your introduction and cover letter accordingly.

• Tighten your statistics: If JAMA flagged methodological issues, address them thoroughly. Post-hoc analyses need to be clearly labeled. Multiplicity issues need adjustment. Sensitivity analyses need to be present and discussed.

• Rewrite your cover letter from scratch: Don't recycle the JAMA version. Each journal wants to know specifically why your paper fits their scope and readership.

If JAMA rejected your paper because the trial is too practice-changing to sit in a specialty journal but JAMA couldn't accommodate it, NEJM is the next stop. NEJM's acceptance rate (~5%) is similar to JAMA's, but the editorial emphasis is different. Where JAMA wants broad clinical relevance, NEJM wants immediate impact on practice. A trial that changes what doctors do tomorrow morning is NEJM's sweet spot. NEJM's review process is faster than JAMA's. Median first decision is about 21 days.

Best for: Large clinical trials with clear, immediate practice implications. Drug and device trials with definitive results.

The Lancet shares JAMA's interest in clinical medicine but adds a global health lens. If JAMA rejected your paper for being "too focused on a specific healthcare context," The Lancet might find the global health dimensions JAMA didn't prioritize. The Lancet is also more receptive to public health research, policy-relevant studies, and large epidemiological analyses than JAMA tends to be. If your paper sits at the boundary of clinical medicine and public health, The Lancet is the right call.

Best for: Clinical research with global health implications. Large trials from international settings. Health policy research with clinical outcomes.

The BMJ is particularly strong for evidence synthesis, health services research, and clinical studies with policy implications. If JAMA rejected your systematic review or meta-analysis, The BMJ should be your first alternative. The journal publishes more reviews and meta-analyses than JAMA, NEJM, or The Lancet. The BMJ's open peer review system means reviewers' identities are disclosed to authors. This tends to produce more constructive and balanced feedback. If your JAMA experience involved harsh anonymous reviews, you might appreciate The BMJ's transparency.

Best for: Systematic reviews, meta-analyses, health services research, clinical practice studies, and papers with guideline implications.

JAMA Internal Medicine is the top destination for internal medicine research that's too specialized for JAMA's general readership. Despite being a "specialty" journal, its IF (~23) places it among the leading specialty medical journals, and papers published here carry substantial clinical weight. The journal has a reputation for publishing studies that challenge conventional wisdom. If your paper shows that a widely used treatment doesn't work as well as everyone thinks, or that a neglected approach deserves more attention, JAMA Internal Medicine rewards that contrarian evidence.

Best for: Internal medicine clinical trials, health services research, studies that challenge established practice, and research on healthcare delivery and outcomes.

Annals publishes the American College of Physicians clinical guidelines, giving it direct influence on internal medicine practice. If your paper could inform a guideline update, Annals is where it will have the most direct impact. The journal values systematic reviews and evidence synthesis particularly highly. Annals publishes the "In the Clinic" series and clinical practice reviews that clinicians actually read and apply. If your research connects to that practical, guideline-oriented mission, it's a strong fit.

Best for: Systematic reviews that inform guidelines, screening and prevention studies, primary care clinical trials, and health services research.

PLOS Medicine fills a niche as the highest-impact open-access general medical journal. It's an excellent alternative when JAMA rejected your paper for scope reasons but you want broad readership without a paywall. The journal is particularly receptive to global health research, studies from low- and middle-income countries, and research addressing health equity. PLOS offers APC waivers for qualifying authors, which makes it accessible to researchers who can't pay publication fees.

Best for: Global health clinical research, health equity studies, and clinical research where open access is important for reaching the intended audience.

If JAMA found your paper interesting but not competitive for the flagship, JAMA Network Open is often the logical next step. It publishes across all clinical specialties, accepts around 15% of submissions, and provides full open access. Don't think of JAMA Network Open as a consolation prize. The journal has established itself as a legitimate venue for solid clinical research, and its open-access model means your paper may actually reach more readers than it would behind JAMA's paywall.

Best for: Solid clinical research across any specialty. Papers where JAMA's scope fit was fine but competition for space was the issue.

• How to choose a journal for your paper
• Signs your paper is not ready to submit
• What pre-submission peer review includes

Before you resubmit, run your manuscript through a manuscript scope and readiness check to check fit, structure, and editorial risk before the next submission.

In our pre-submission review work with manuscripts targeting JAMA, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Specialty findings without cross-specialty relevance. JAMA's editorial standard requires that findings matter to practicing clinicians across medicine, not just to specialists in one disease area. We see this failure as the most common pattern in JAMA desk rejections we review: excellent hepatology trials, rigorous endocrinology cohort studies, and strong psychiatry biomarker papers that do not answer a question cardiologists, oncologists, or internists outside that specialty would find directly relevant. In our review of JAMA submissions, we find that editors consistently return papers where the readership relevance is narrow even when the methodology is exemplary.

Methodological reporting gaps. JAMA's statistical reviewers are among the most thorough in clinical publishing. We see this pattern in clinical trial manuscripts we review for JAMA with missing CONSORT flow diagrams, pre-specified endpoints that shifted post-hoc without adequate justification, or observational analyses with insufficient STROBE compliance. These gaps generate desk rejection even when the scientific question is clinically important.

Submission timing following recent JAMA coverage of the same topic. Editors actively avoid publishing multiple papers addressing the same clinical question within a short window. We see this failure pattern regularly: strong manuscripts arriving shortly after JAMA published a competing trial or landmark analysis on the identical clinical question. The editorial response is not a quality judgment but a scheduling one.

Statistically significant findings with clinically marginal effect sizes. JAMA editors evaluate whether the magnitude of the effect, not just its statistical significance, justifies guideline or practice change. Trials producing a 1-2% absolute risk reduction on a non-fatal surrogate endpoint consistently face harder editorial scrutiny than trials producing smaller effects on mortality or patient-reported outcomes.

SciRev community data for JAMA confirms desk rejections typically arrive within days, with post-review first decisions within 4-6 weeks, consistent with the fast editorial cadence JAMA maintains.

Think twice before submitting to NEJM or The Lancet if JAMA identified methodological gaps; those journals have equally rigorous standards and the same issues will surface.